Da An Gene Co Ltd of Sun Yat-Sen University (SHE:002030) — Market Cap & Net Worth
Market Cap & Net Worth: Da An Gene Co Ltd of Sun Yat-Sen University (002030)
Da An Gene Co Ltd of Sun Yat-Sen University (SHE:002030) has a market capitalization of $1.14 Billion (CN¥7.79 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #8495 globally and #2093 in its home market, demonstrating a 2.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Da An Gene Co Ltd of Sun Yat-Sen University's stock price CN¥5.55 by its total outstanding shares 1403446032 (1.40 Billion). Review 002030 total liabilities to assess the company's total debt and financial obligations.
Da An Gene Co Ltd of Sun Yat-Sen University Market Cap History: 2015 to 2026
Da An Gene Co Ltd of Sun Yat-Sen University's market capitalization history from 2015 to 2026. Data shows change from $3.14 Billion to $1.14 Billion (-9.31% CAGR).
Da An Gene Co Ltd of Sun Yat-Sen University Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Da An Gene Co Ltd of Sun Yat-Sen University's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.62x
Da An Gene Co Ltd of Sun Yat-Sen University's market cap is 1.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.95 Billion | $1.61 Billion | $106.69 Million | 1.21x | 18.24x |
| 2017 | $1.56 Billion | $1.54 Billion | $86.45 Million | 1.01x | 18.06x |
| 2018 | $940.67 Million | $1.48 Billion | $101.58 Million | 0.64x | 9.26x |
| 2019 | $1.07 Billion | $1.10 Billion | $92.18 Million | 0.97x | 11.60x |
| 2020 | $3.51 Billion | $5.34 Billion | $2.45 Billion | 0.66x | 1.43x |
| 2021 | $3.34 Billion | $7.66 Billion | $3.62 Billion | 0.44x | 0.92x |
| 2022 | $2.74 Billion | $12.05 Billion | $5.41 Billion | 0.23x | 0.51x |
| 2023 | $1.98 Billion | $1.18 Billion | $104.66 Million | 1.68x | 18.95x |
| 2024 | $1.17 Billion | $853.02 Million | -$925.17 Million | 1.37x | N/A |
| 2025 | $1.22 Billion | $757.66 Million | -$744.38 Million | 1.62x | N/A |
Competitor Companies of 002030 by Market Capitalization
Companies near Da An Gene Co Ltd of Sun Yat-Sen University in the global market cap rankings as of June 19, 2026.
Key companies related to Da An Gene Co Ltd of Sun Yat-Sen University by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Da An Gene Co Ltd of Sun Yat-Sen University Historical Marketcap From 2015 to 2026
Between 2015 and today, Da An Gene Co Ltd of Sun Yat-Sen University's market cap moved from $3.14 Billion to $ 1.14 Billion, with a yearly change of -9.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.14 Billion | -6.88% |
| 2025 | CN¥1.22 Billion | +4.93% |
| 2024 | CN¥1.17 Billion | -41.17% |
| 2023 | CN¥1.98 Billion | -27.75% |
| 2022 | CN¥2.74 Billion | -17.74% |
| 2021 | CN¥3.34 Billion | -4.95% |
| 2020 | CN¥3.51 Billion | +228.37% |
| 2019 | CN¥1.07 Billion | +13.64% |
| 2018 | CN¥940.67 Million | -39.76% |
| 2017 | CN¥1.56 Billion | -19.73% |
| 2016 | CN¥1.95 Billion | -37.97% |
| 2015 | CN¥3.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Da An Gene Co Ltd of Sun Yat-Sen University was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.14 Billion USD |
| MoneyControl | $1.14 Billion USD |
| MarketWatch | $1.14 Billion USD |
| marketcap.company | $1.14 Billion USD |
| Reuters | $1.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Da An Gene Co Ltd of Sun Yat-Sen University
Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coro… Read more